
RESPIRI LIMITED

NEW CHAIR APPOINTED

The Directors of Respi Limited (RSH), Brendan Mason, Non-Executive Director and Mario Gattino, Executive Director (CEO) are pleased to announce that following a meeting of the Board yesterday, Mr Mark Ziirsen has been appointed as its new Chairman.

Mark is a former Director Finance and IT, Asia Pacific at Cochlear Limited (ASX:COH) and Chief Financial Officer of Admedus Limited (ASX:AHZ). Mark is a highly strategic senior finance leader with proven commercial acumen. He brings to Respi a strong track record of delivering growth and significant improvement across multiple industry sectors and geographies in executive roles with market leading international organisations. His strong credentials in finance are complemented by extensive corporate finance, governance, risk management, M&A and investor relations skills. Mark was also a Non-Executive Director and Chair of the Audit Committee of ASX listed SmartTrans Holdings Limited (ASX:SMA).

Mark and Non-Executive Director Brendan Mason were also appointed to the Company Audit & Risk and Nomination & Remuneration Committees.

-End-

Contact:

Jenni Lightowers
Company Secretary
1800 476 632

About Respiri Limited (ASX:RSH)

Respiri is a health technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices.

Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respiri's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respiri has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respiri products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun.

Respiri is especially proud of its recent de-risking of milestones. The substantial achievements over the past 18 months place Respiri in a lower risk position and on the cusp of commercialisation compared to the vast majority of medical device and biotech companies